Exploring the treatment gap among patients with osteoporosis-related fractures in France - Université de Picardie Jules Verne Accéder directement au contenu
Article Dans Une Revue Archives of Osteoporosis Année : 2022

Exploring the treatment gap among patients with osteoporosis-related fractures in France

Résumé

The use of anti-osteoporosis treatment following a diagnosis of osteoporosis with fracture or a relevant fragility fracture remains low in France. Initiating an anti-resorptive may reduce the incidence of a subsequent fracture by 60%. Purpose To describe real-world osteoporosis treatment patterns in individuals with a fragility fracture in France and to explore the impact of initiating treatment on the risk of subsequent fracture. Methods A retrospective cohort study, using the national French Health Insurance claims database. Males and females 50 years and over, with a hospital discharge diagnosis of osteoporosis with fracture or a relevant fragility fracture between 2011 and 2014, were included and followed until death or the end of 2016, whichever came first. The primary outcome was the proportion of patients receiving anti-osteoporosis treatments prior to and post-index fracture. Change in fracture rates before and after treatment initiation was assessed in an exploratory analysis. Results A total of 574,133 patients (138,567 males, 435,566 females) had a qualifying index fracture. The proportion of patients receiving any anti-osteoporosis treatment increased pre-index fracture to post-index fracture from 2.2 to 5.6% among males, and from 11.8 to 18.2% among females. Oral bisphosphonates were the most prescribed anti-osteoporosis treatment for both males and females among post-index fractures (60.6% and 68.8% of patients initiating treatment). Following initiation of anti-resorptives, the incidence of subsequent fracture was reduced by 60% (rate ratio (RR): 0.40, 95% confidence interval [CI]: 0.34-0.45). Conclusion Anti-osteoporosis treatment following an index fracture in France remains low. Improved identification and pharmacologic management of patients at risk of fragility fractures are necessary to reduce the risk of subsequent fractures.
Fichier non déposé

Dates et versions

hal-03566151 , version 1 (11-02-2022)

Identifiants

Citer

Patrice Fardellone, Lianne Barnieh, Nadia Quignot, Gaelle Gusto, Artak Khachatryan, et al.. Exploring the treatment gap among patients with osteoporosis-related fractures in France. Archives of Osteoporosis, 2022, 17 (1), ⟨10.1007/s11657-021-01041-1⟩. ⟨hal-03566151⟩
23 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More